(May 17, 2019, 9:14 AM EDT) -- SAN FRANCISCO — A federal district court did not err in dismissing a second amended complaint (SAC) in a shareholder class action against a medical device maker and two of its senior executives because the lead plaintiff in the action failed to plead falsity or scienter in making her federal securities claims, the defendants argue in an April 15 appellee brief filed in the Ninth Circuit U.S. Court of Appeals (Vicky Nguyen v. Endologix Inc., et al., No. 18-56322, 9th Cir.)....